Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Updated COVID-19 vaccines protect adults with autoimmune rheumatic conditions (opens in a new tab)

news-medical.net · 2026-09-09

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 4 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Four of five check out.

  • 4 supported
  • 1 overstated
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedThe first author said the results provide real-world evidence that updated vaccines continue to offer substantial protection in this medically vulnerable population.View evidenceHide evidence

Why this verdict

The profile indicates that the authors conclude updated vaccination provides significant protection in this medically vulnerable population, so the quoted interpretation is directionally aligned with the paper. However, the story’s wording that vaccines 'continue to offer substantial protection' is a protection/causal-strength formulation based on a retrospective observational EHR cohort; the abstract supports adjusted associations, not a definitive causal protection estimate. The story’s body caveats partly temper this, but the quoted claim itself outruns the observational evidence.

1

Study evidence

Receipt of COVID-19 vaccines was associated with progressively lower adjusted odds of COVID-19-related hospitalization compared with no vaccination.initial series aOR 0.59 (95% CI 0.56–0.63); boosted series aOR 0.29 (95% CI 0.27–0.31); updated series aOR 0.31 (95% CI 0.28–0.34) (each vs no vaccine)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024.”
Claim 2 of 5SupportedAn Arthritis & Rheumatology analysis studied 60,980 U.S. adults with autoimmune rheumatic conditions who developed COVID-19 between December 2020 and August 2024.View evidenceHide evidence

As stated60,980

Why this verdict

The abstract-level profile explicitly describes a retrospective cohort using N3C data on adults with autoimmune rheumatic conditions and incident COVID-19 from December 2020 to August 2024, with a cohort size of 60,980.

1

Study evidence

Receipt of COVID-19 vaccines was associated with progressively lower adjusted odds of COVID-19-related hospitalization compared with no vaccination.initial series aOR 0.59 (95% CI 0.56–0.63); boosted series aOR 0.29 (95% CI 0.27–0.31); updated series aOR 0.31 (95% CI 0.28–0.34) (each vs no vaccine)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024.”
Claim 3 of 5SupportedThose who received booster or updated (2023-2024) COVID-19 vaccines were less likely to be hospitalized for COVID-19 than people who received only the initial series vaccines or who were unvaccinated.View evidenceHide evidence

Why this verdict

The paper reports lower adjusted odds of COVID-19-related hospitalization for boosted and updated-vaccine groups versus no vaccination, and the profile also states booster/updated vaccination was associated with lower hospitalization odds compared with the initial series alone. The story frames this as being 'less likely' rather than proving causation, which is consistent with the observational association in the abstract.

1

Study evidence

Receipt of COVID-19 vaccines was associated with progressively lower adjusted odds of COVID-19-related hospitalization compared with no vaccination.initial series aOR 0.59 (95% CI 0.56–0.63); boosted series aOR 0.29 (95% CI 0.27–0.31); updated series aOR 0.31 (95% CI 0.28–0.34) (each vs no vaccine)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024.”
2

Study evidence

Absolute risk reduction for COVID-19-related hospitalization comparing patients who received only the initial vaccine series versus those who received a booster/updated vaccine: 5.6%.5.6% (absolute risk reduction)

“Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.”
Claim 4 of 5SupportedCompared with no vaccination, completion of the initial series, booster vaccination, and updated vaccination were associated with 41%, 71%, and 69% lower adjusted odds of COVID-19-related hospitalization, respectively.View evidenceHide evidence

As stated41%, 71%, and 69% lower adjusted odds

Why this verdict

The reported adjusted odds ratios versus no vaccination are initial series aOR 0.59, booster aOR 0.29, and updated series aOR 0.31, corresponding to 41%, 71%, and 69% lower adjusted odds of COVID-19-related hospitalization, respectively.

1

Study evidence

Receipt of COVID-19 vaccines was associated with progressively lower adjusted odds of COVID-19-related hospitalization compared with no vaccination.initial series aOR 0.59 (95% CI 0.56–0.63); boosted series aOR 0.29 (95% CI 0.27–0.31); updated series aOR 0.31 (95% CI 0.28–0.34) (each vs no vaccine)

“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024.”
Claim 5 of 5SupportedAmong patients who had received only the initial vaccine series versus booster/updated vaccine, the absolute risk reduction was 5.6%.View evidenceHide evidence

As stated5.6%

Why this verdict

The abstract-level profile reports an absolute risk reduction of 5.6% for COVID-19-related hospitalization comparing initial-series-only vaccination with booster/updated vaccination. The story accurately states the magnitude, although the abstract does not provide the ARR computation method or uncertainty interval.

1

Study evidence

Absolute risk reduction for COVID-19-related hospitalization comparing patients who received only the initial vaccine series versus those who received a booster/updated vaccine: 5.6%.5.6% (absolute risk reduction)

“Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Primary outcome: COVID-19-related hospitalization; secondary outcomes included mechanical ventilation/ECMO and death.

    The story accurately focuses on the primary hospitalization outcome, but it does not mention that mechanical ventilation/ECMO and death were also assessed. This omission does not undermine the hospitalization claims, but it leaves out part of the paper’s outcome scope.

    From Retrospective cohort (secondary EHR data)

  • ARR-specific limitations: the abstract does not specify how the 5.6% ARR was computed and does not report a confidence interval or other uncertainty measure for it.

    The story reports the ARR as a point estimate but does not mention the abstract-level uncertainty and methods limitations around that estimate.

    From retrospective cohort

  • Generalizability and subgroup context: the cohort was 76% female and 74% non-Hispanic White, and only 10% received an updated 2023–2024 vaccine.

    These abstract-reported cohort composition details are not reflected in the story, though they are relevant to interpreting representativeness and the size of the updated-vaccine subgroup.

    From Retrospective cohort (secondary EHR data); retrospective cohort

6 things the story did carry across
  • Study design and data source: retrospective cohort analysis using National Clinical Cohort Collaborative (N3C) electronic health record data.
  • Population and study window: 60,980 adults with autoimmune rheumatic conditions and incident COVID-19 from December 2020 through August 2024.
  • Exposure categories: unvaccinated, initial vaccine series, booster, and updated 2023–2024 COVID-19 vaccine status.
  • Main adjusted hospitalization results versus no vaccination: initial series aOR 0.59, booster aOR 0.29, updated vaccine aOR 0.31.
  • Secondary comparative contrast: absolute risk reduction of 5.6% for hospitalization comparing booster/updated vaccination with initial-series-only vaccination.
  • Key limitation: retrospective observational EHR design is subject to residual confounding and bias despite multivariable adjustment.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess the association between COVID-19 vaccination status (unvaccinated, initial series, booster, updated 2023–2024 vaccine) and severe COVID-19 outcomes in adults with autoimmune rheumatic conditions using N3C data.Retrospective cohort (secondary EHR data)Expand

In plain English

Retrospective cohort study of 60,980 adults with autoimmune rheumatic conditions in N3C (Dec 2020–Aug 2024) found progressively lower adjusted odds of COVID-19-related hospitalization for those receiving an initial vaccine series, a booster, or an updated (2023–2024) vaccine versus no vaccination; mechanical ventilation/ECMO and death were also assessed but numerical results for those outcomes are not reported in the abstract.

Key findings

  • Receipt of COVID-19 vaccines was associated with progressively lower adjusted odds of COVID-19-related hospitalization compared with no vaccination.initial series aOR 0.59 (95% CI 0.56–0.63); boosted series aOR 0.29 (95% CI 0.27–0.31); updated series aOR 0.31 (95% CI 0.28–0.34) (each vs no vaccine)
  • Among patients who had received only the initial vaccine series versus those who received a booster or updated vaccine, the absolute risk reduction in hospitalization was reported.Absolute risk reduction 5.6% (initial series only vs booster/updated)
“We conducted a retrospective cohort study using National Clinical Cohort Collaborative (N3C) data on adults with autoimmune rheumatic conditions and incident COVID-19 occurring between December 2020 and August 2024.”
What this piece can’t prove
  • Retrospective observational design using secondary EHR data (N3C) subject to potential residual confounding despite multivariable adjustment.
  • Abstract does not report numerical results or precision estimates for mechanical ventilation/ECMO and death.

1 further detail could not be confirmed from the summary.

2secondary dataQuantify comparative benefit of booster/updated vaccination vs initial series alone (e.g., absolute risk reduction) among infected patients with autoimmune rheumatic conditions.retrospective cohortExpand

In plain English

In a retrospective cohort of 60,980 adults with autoimmune rheumatic conditions and incident COVID-19 (Dec 2020–Aug 2024) using N3C data, the authors report an absolute risk reduction of 5.6% for COVID-19-related hospitalization when comparing patients who had received a booster/updated (2023–2024) COVID-19 vaccine versus those who had received only the initial vaccine series.

Key findings

  • Absolute risk reduction for COVID-19-related hospitalization comparing patients who received only the initial vaccine series versus those who received a booster/updated vaccine: 5.6%.5.6% (absolute risk reduction)
“Among patients who had received only the initial vaccine series versus a booster/updated vaccine, the absolute risk reduction was 5.6%.”
What this piece can’t prove
  • Abstract reports a retrospective observational cohort—potential for residual confounding and bias inherent to non-randomized designs.
  • Cohort demographics skewed (76% female; 74% non-Hispanic White), which may limit generalizability to more diverse populations.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

POS1235 ASSESSMENT OF RISK FACTORS FOR HOSPITALIZATION OF AUTOIMMUNE AND RHEUMATIC DISEASE PATIENTS WITH COVID-19 – A SINGLE CENTRE OBSERVATIONAL STUDY

Annals of the Rheumatic Diseases · 2021 · Crossref

Source (opens in a new tab)
Candidate

POS0071 IMMUNOMODULATORY TREATMENT AND IMMUNE RESPONSES TO COVID-19 BOOSTER SHOTS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINE RESPONSE IN RHEUMATOLOGY PATIENTS (COVER) STUDY

Annals of the Rheumatic Diseases · 2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.